- Current report filing (8-K)
04 3월 2009 - 6:03AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 3, 2009
ALLOS
THERAPEUTICS, INC
(Exact name of
registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No.)
|
11080
CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
|
Registrants telephone
number, including area code:
(303) 426-6262
Not
applicable
(Former name or former
address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
|
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
Section 2 Financial Information
Item 2.02 Results of Operations and Financial Condition.
On March 3, 2009, Allos Therapeutics, Inc.,
a Delaware corporation (the Company), issued a press release reporting
results for its fiscal year ended December 31, 2008 and outlining its key
objectives for 2009.
The press release is attached hereto as Exhibit 99.1,
which is furnished under Item 2.02 of this report and shall not be deemed to be
filed for purposes of Section 18 of the Securities Exchange Act of 1934
(the Exchange Act) or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, regardless of any general
incorporation language in such filing.
Section 9 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press
Release, dated March 3, 2009, entitled Allos Therapeutics Reports 2008 Results.
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Dated: March 3,
2009
|
|
|
|
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Marc H. Graboyes
|
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice President,
General Counsel
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated
March 3, 2009, entitled Allos
Therapeutics Reports 2008 Results.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024